Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 59 of the 63 references it cites were found in a registry or an index; 8 of the 36 sources its claims cite were checked for support.

Mitochondrial Dysfunction Induced by Sertraline, an Antidepressant Agent

Open access
Li, Yan, Couch, Letha, Higuchi, Masahiro, Fang, Jia-Long, Guo, Lei · 2012 · Toxicological Sciences

Abstract

Sertraline, a selective serotonin reuptake inhibitor, has been used for the treatment of depression. Although it is generally considered safe, cases of sertraline-associated liver injury have been documented; however, the possible mechanism of sertraline-associated hepatotoxicity is entirely unknown. Here, we report that mitochondrial impairment may play an important role in liver injury induced by sertraline. In mitochondria isolated from rat liver, sertraline uncoupled mitochondrial oxidative phosphorylation and inhibited the activities of oxidative phosphorylation complexes I and V. Additionally, sertraline induced Ca(2+)-mediated mitochondrial permeability transition (MPT), and the induction was prevented by bongkrekic acid (BA), a specific MPT inhibitor targeting adenine nucleotide translocator (ANT), implying that the MPT induction is mediated by ANT. In freshly isolated rat primary hepatocytes, sertraline rapidly depleted cellular adenosine triphosphate (ATP) and subsequently induced lactate dehydrogenase leakage; both were attenuated by BA. Our results, including ATP depletion, induction of MPT, inhibition of mitochondrial respiration complexes, and uncoupling oxidative phosphorylation, indicate that sertraline-associated liver toxicity is possibly via mitochondrial dysfunction.

Overview

CoChat Summary

TL;DR

Sertraline caused mitochondrial dysfunction in rat liver mitochondria and primary hepatocytes, including ATP depletion, oxidative phosphorylation uncoupling, inhibition of complexes I and V, and Ca²⁺-mediated mitochondrial permeability transition via ANT. These findings suggest mitochondrial impairment may contribute to sertraline-associated liver toxicity.

Key findings

  • In rat primary hepatocytes, sertraline depleted ATP early: at 37.5 µM, approximately 37%, 64%, and 90% of ATP was depleted at 0.5, 2, and 6 h, respectively; at 100 µM, nearly complete ATP depletion occurred at 0.5 h without obvious LDH release.
  • Cytotoxicity followed ATP depletion: significant LDH release began at 50 µM at 2 h (~55% vs. 24% control), and at 6 and 24 h sertraline caused profound damage starting at 37.5 µM with ~77% and ~100% LDH release, respectively.
  • In isolated rat liver mitochondria, sertraline uncoupled oxidative phosphorylation and inhibited complexes I and V with IC50s of 88.6 and 69.0 µM, respectively; complexes II and IV were unaffected even at 100 µM, and complex III inhibition at 100 µM was not statistically significant.
  • Sertraline induced Ca²⁺-mediated mitochondrial permeability transition and inhibited ANT activity by approximately 40% at 100 µM; bongkrekic acid prevented MPT, ATP depletion, and LDH release, whereas cyclosporine A did not.

Methods

  • Rat primary hepatocytes were isolated from male Sprague Dawley rats (6–8 weeks old), cultured, and treated with sertraline in DMSO at concentrations up to 100 µM; cellular ATP was measured with CellTiter-Glo and LDH release was used as a cell death measure.
  • Isolated rat liver mitochondria were used to measure oxygen consumption with a Clark-type electrode using glutamate/malate or succinate, individual oxidative phosphorylation complex I–V activities, MPT by mitochondrial swelling at 540 nm in the presence of 20 µM Ca²⁺, and ANT activity spectrophotometrically.
  • Data are presented as mean ± SD of at least three independent experiments; statistical significance was determined by one-way ANOVA with Dunnett’s tests or two-way ANOVA with Bonferroni’s posttest, with p < 0.05 considered significant.

Limitations

  • The paper states that the sertraline concentrations used were higher than clinical concentrations; clinical Cmax after a 400 mg oral dose was ~0.74 µM, while toxic effects in this study started at 37.5 µM, close to 100-fold the reported Cmax.
  • The paper states that mitochondrial impairment may not be the sole contributor to sertraline-induced hepatotoxicity, based on preliminary glucose/galactose HepG2 results, and that future studies are needed on drug metabolism and CYP enzymes.
  • Evident from the text: the study is in vitro only, using male rat primary hepatocytes and isolated rat liver mitochondria, with no in vivo liver injury model or human validation; parent drug versus metabolite contributions are not fully resolved, although SKF 525-A enhanced toxicity suggests the parent form is more toxic.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/toxsci/kfs100

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

7 Valid · 0 Not valid · 21 Not checked · 45 Own results and interpretations

42 more claims

Create a free account to see all 73 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 13
  • It may state two separate claims as one. 15

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

1 of 1

Citations

Cites

Show all 63 references

Research works printed but not linked: 2

  1. Galán Navarro, 2001, Hepatitis aguda colestásica probablemente causada por sertralina, Rev. Esp. Enferm. Dig., 93, 822
  2. Zoloft, 1997, Roering Division of Pfizer, Inc

Cited by

See all 120

Metadata

Authors
Li, Y., Couch, L., Higuchi, M., Fang, J.-L., & Guo, L.
Affiliations
  • National Center for Toxicological Research (US)
  • University of Arkansas for Medical Sciences (US)
Venue
Toxicological Sciences
Published
2012-03-02
Volume
127
Issue
2
Pages
582-591
ISSN
  • 1096-0929 (ISSN-L)
  • 1096-6080
OpenAlex
W1994651650
Cited by
120
References
63
Citations by year
2026: 9 · 2025: 7 · 2024: 14 · 2023: 7 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 6 · 2018: 9 · 2017: 13 · 2016: 10 · 2015: 7 · 2014: 9 · 2013: 7 · 2012: 2
FWCI
9.03
Type
journal article
Language
en
Open access
Locations
  • Toxicological Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (FD999999)
  • U.S. Food and Drug Administration
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords
sertraline, selective serotonin reuptake inhibitors, hepatotoxicity, mitochondrial dysfunction, mitochondrial permeability transition, adenine nucleotide translocase, bongkrekic acid, mitochondrial uncoupling, complex I, ATP synthase, ATP depletion, lactate dehydrogenase leakage, drug-induced liver injury
MeSH terms
Mitochondrial Permeability Transition Pore, Mitochondrial ADP, ATP Translocases, Adenosine Triphosphate, Animals, Antidepressive Agents, Bongkrekic Acid, Cells, Cultured, Dose-Response Relationship, Drug, Energy Metabolism, L-Lactate Dehydrogenase, Male, Mitochondria, Liver, Oxidative Phosphorylation, Time Factors, Cyclosporine, Rats, Sprague-Dawley, Selective Serotonin Reuptake Inhibitors, Risk Assessment, Sertraline, Hepatocytes, Mitochondrial Diseases, Mitochondrial Membrane Transport Proteins, Electron Transport Chain Complex Proteins, Rats, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mitochondrial Dysfunction Induced by Sertraline, an Antidepressant Agent. https://app.cochat.ai/papers/10.1093/toxsci/kfs100
The paper
Li, Y., Couch, L., Higuchi, M., Fang, J.-L., & Guo, L. (2012). Mitochondrial Dysfunction Induced by Sertraline, an Antidepressant Agent. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfs100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.